This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Keating NL et al. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448–4456
Tsai HK et al. (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99: 1516–1524
D'Amico AV et al. (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25: 2420–2425
Smith MR et al. (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87: 599–603
Yannucci J et al. (2006) The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 176: 520–525
Smith MR et al. (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91: 1305–1308
Acknowledgements
The synopsis was written by Rachel Murphy, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Corsello, S., Kantoff, P. Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?. Nat Rev Urol 5, 80–81 (2008). https://doi.org/10.1038/ncpuro1015
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro1015